Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Dreyling

Showing results (141-150 of 336) with videos related to

Pageof 34
Sort By:
Annals of Hematology|April 15, 2025
Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma - an open-label, multicentre phase I/II study (DSHNHL-R6)Stephan Fuhrmann, Maike Nickelsen, Justin Hasenkamp, et al.
Cancers|June 2, 2021
CAR T-Cells for CNS Lymphoma: Driving into New Terrain?Philipp Karschnia, Jens Blobner, Nico Teske, et al.
Healthcare (Basel, Switzerland)|September 23, 2022
Tackling Mantle Cell Lymphoma in EuropeDenis Horgan, Jan Walewski, Igor Aurer, et al.
Haematologica|December 25, 2016
Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphomaAndrew Grigg, Martin J S Dyer, Marcos González Díaz, et al.
European Radiology|March 31, 2018
Structured reporting adds clinical value in primary CT staging of diffuse large B-cell lymphomaFranziska Schoeppe, Wieland H Sommer, Dominik Nörenberg, et al.
Neuro-Oncology|May 19, 2017
Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphomaFranziska S Thaler, Sarah A Laurent, Marion Huber, et al.
Trials|September 1, 2019
Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trialLaila König, Martin Dreyling, Jan Dürig, et al.
Frontiers in Oncology|June 13, 2020
The Role of BAFF-R Signaling in the Growth of Primary Central Nervous System LymphomaXiaolan Zhou, Matthias Mulazzani, Iven-Alex von Mücke-Heim, et al.
Leukemia & Lymphoma|September 5, 2017
Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCLMareike Frick, Marcus Bettstetter, Simone Bertz, et al.
Leukemia & Lymphoma|November 24, 2015
Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an updateBruce D Cheson, Wolfram Brugger, Gandhi Damaj, et al.
Pageof 34

Showing results (141-150 of 336) with videos related to

Sort By:
Pageof 34
Annals of Hematology|April 15, 2025
Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma - an open-label, multicentre phase I/II study (DSHNHL-R6)Stephan Fuhrmann, Maike Nickelsen, Justin Hasenkamp, et al.
Cancers|June 2, 2021
CAR T-Cells for CNS Lymphoma: Driving into New Terrain?Philipp Karschnia, Jens Blobner, Nico Teske, et al.
Healthcare (Basel, Switzerland)|September 23, 2022
Tackling Mantle Cell Lymphoma in EuropeDenis Horgan, Jan Walewski, Igor Aurer, et al.
Haematologica|December 25, 2016
Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphomaAndrew Grigg, Martin J S Dyer, Marcos González Díaz, et al.
European Radiology|March 31, 2018
Structured reporting adds clinical value in primary CT staging of diffuse large B-cell lymphomaFranziska Schoeppe, Wieland H Sommer, Dominik Nörenberg, et al.
Neuro-Oncology|May 19, 2017
Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphomaFranziska S Thaler, Sarah A Laurent, Marion Huber, et al.
Trials|September 1, 2019
Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trialLaila König, Martin Dreyling, Jan Dürig, et al.
Frontiers in Oncology|June 13, 2020
The Role of BAFF-R Signaling in the Growth of Primary Central Nervous System LymphomaXiaolan Zhou, Matthias Mulazzani, Iven-Alex von Mücke-Heim, et al.
Leukemia & Lymphoma|September 5, 2017
Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCLMareike Frick, Marcus Bettstetter, Simone Bertz, et al.
Leukemia & Lymphoma|November 24, 2015
Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an updateBruce D Cheson, Wolfram Brugger, Gandhi Damaj, et al.
Pageof 34